Aeglea BioTherapeutics Investor Presentation Deck

Targeting new heights in the treatment of IBD SPYRE THERAPEUTICS THREE-PILLAR STRATEGY Y KE OPPORTUNITY FOR BEST-IN-CLASS LONG-ACTING ANTIBODIES SUBCUTANEOUS (SC) Q8-12W DOSING RATIONAL THERAPEUTIC COMBINATIONS PRECISION IMMUNOLOGY PARALLEL LEAD PROGRAMS AGAINST HIGH VALUE TARGETS TARGET a437 TL1A IL-23 Novel MOA a437 + IL-23 a437 + TL1A TL1A + IL-23 PROGRAM SPY001 SPY002 SPY003 SPY004 SPY130 SPY120 SPY230 DISCOVERY IND-ENABLING CLINICAL Phase 1 interim data expected YE24 Phase 1 interim data expected 1H25

View entire presentation